EURACTIV - Belgium ranks among the European leaders in pharmaceutical research, patents, exports and jobs. Yet only half of the innovative medicines approved at the European level between 2021 and 2024 are available to Belgian patients, and those that do arrive take on average a year and a half. Read more

EU PERSPECTIVES - Europe fears that a new US policy aimed at lowering medicine prices for Americans could ultimately drive up costs for European healthcare systems and affect access to medicines. Brussels will now assess whether the move could delay drug launches, raise prices or push pharmaceutical investment out of the EU. Read more

EU PERSPECTIVES - Millions of medicine packs reach European pharmacies every day, on time, regardless of weather, shortages, or logistical complexity. The companies making that happen are largely invisible in EU policy discussions. The models they are paid by are 30 to 40 years out of date — and if nothing changes, you may one day walk into...

EU PERSPECTIVES - Expand, scrap, or keep it as it is? It depends on who you ask. A proposed extension of market protection for selected biotech medicines is dividing Brussels: industry is pushing for a wider scope, some MEPs want it removed entirely, while the European Commission is defending its current design. Read more

EURACTIV - The introduction of copycat versions of expensive biologic medicines has transformed treatment access for millions of Europeans living with immune-mediated inflammatory diseases, as cost savings from biosimilar competition are increasingly being reinvested into broader patient care. Read more

EURACTIV - The Biotech Act can help create a new confidence, proving that Europe wants to remain competitive in biotechnology, says Belgian life sciences leader Frédéric Druck. Read more

EUROPEAN BIOTECHNOLOGY MAGAZINE - The COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing capability and global deployment, pushing RNA therapeutics into the public spotlight. But according to...

EU PERSPECTIVES - When it comes to cancer medicines, the EU should look beyond a purely 'Made in Europe' approach and embrace 'Made with Europe', according to Giancarlo Benelli, Head of Europe at BeOne Medicines. "Cancer does not have borders," he says, as many European patients still wait too long for innovative treatments. He argues that...

EU PERSPECTIVES - How can Europe attract more doctors, nurses and other healthcare workers — and, crucially, keep them in the profession? As staff shortages deepen across the bloc, the European Parliament has backed a plan to recruit at least one million people over the next seven years. But lawmakers face a growing dilemma: how to fill the...

EU PERSPECTIVES - The Ebola outbreak in Africa is becoming more than a public health emergency. As EU ministers meet to coordinate their response, the European Commission is presenting the crisis as evidence that Europe must invest more heavily in preparedness, vaccines and medical countermeasures before the next outbreak arrives. Read more